Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Knüttgen, Franziska; Beck, Julia; Dittrich, Marcus; Oellerich, Michael; Zittermann, Armin; Schulz, Uwe; Fuchs, Uwe; Knabbe, Cornelius; Schütz, Ekkehard; Gummert, Jan; Birschmann, Ingvild
• Is Part Of: Transplantation. Volume 106:Issue 3(2022)
• Publication Date: 2022-03
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; Transplantation immunology -- Periodicals; 617.95
• DOI: 10.1097/TP.0000000000003725
• Languages: English
• ISSNs: 0041-1337

Abstract

Abstract : Background: Circulating graft-derived cell-free DNA (dd-cfDNA) is a new marker of cardiac allograft damage that is used for noninvasive rejection diagnostics. We performed dd-cfDNA (%) in heart transplant recipients during the first posttransplant year. Methods: In 87 patients, serial dd-cfDNA determination at predefined time-points was performed in 770 single samples. dd-cfDNA fraction (%) was measured using an established universal droplet digital polymerase chain reaction method, providing same-day turn-around. Rejection was diagnosed according to clinical parameters and biopsies. Results: Median dd-cfDNA (%) was high (5.36%) immediately after reperfusion and decreased to a median (interquartile range) of 0.10% (0.05%–0.24%) in clinically stable patients by postoperative day 10. Compared to dd-cfDNA (%) samples in clinically stable patients, values were higher ( P < 0.001) in biopsy-proven rejection ISHLT 1R (0.42% [0.15%–0.53%]) and 2R rejection (0.84% [0.39%–0.97%]). Moreover, dd-cfDNA (%) was already significantly increased 9–30 days before biopsy-proven rejection (0.36% [0.20%–0.61%]). An as yet unknown finding was a slightly, but significantly ( P < 0.0001) higher dd-cfDNA (%) value in samples of stable patients with pericardial effusions (PEs) (n = 94; 0.18% [0.07%–0.30%]) compared to samples of non-PE patients (n = 132; 0.07% [0.04%–0.17%]). Using a cutoff of 0.35%, sensitivity and specificity of dd-cfDNA for cardiac rejection were 0.76 and 0.83 (area under the curve [AUC] ROC-curve: 0.81 [95% confidence interval, 0.73-0.89]). Omitting PE samples from the control group yielded an AUC of 0.86 [95% confidence interval, 0.76-0.95]. Samples drawn <12 hours after endomyocardial biopsy showed high (0.40% [0.15%–1.21%]) dd-cfDNA values, also in ISHLT0R (0.36% [0.10%–0.60%]). Conclusions: dd-cfDNA plasma values were significantly associated with cardiac rejection. However, PE or improper sampling (eg, shortly after biopsy) should be considered as confounders for rejection diagnoses using dd-cfDNA.